Inhibitors stimulating the formation of toxic RAD51 complexes exploit the upregulation of RAD51 (by enhancing filament stability) targeting cancer cells constitutively overexpressing RAD51 and sparing non-tumour cells. The gene discussed is RAD51; the disease is cancer.